{"id":"W1979370923","doi":"10.1016/j.breast.2007.12.004","title":"Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer","year":2008,"lang":"en","type":"review","venue":"The Breast","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"AstraZeneca","keywords":"Fulvestrant; Exemestane; Medicine; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Tolerability; Anastrozole; Clinical trial; Tamoxifen; Cancer; Aromatase inhibitor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005121429,0.0009782284,0.001391937,0.001414913,0.0001938566,0.0006730478,0.0008979039,0.0009563099,0.002533547],"category_scores_gemma":[0.0005682256,0.0001885066,0.0003578745,0.00153657,0.0003653365,0.0009169906,0.0004721682,0.001796988,0.001559024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005026062,"about_ca_system_score_gemma":0.0005468733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000960078,"about_ca_topic_score_gemma":0.00244806,"domain_scores_codex":[0.9998821,0.00001793271,0.0000146257,0.00002161794,0.00005030072,0.0000133779],"domain_scores_gemma":[0.999792,0.0001044584,0.00003547537,0.000005708528,0.00003977861,0.00002247234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001215059,0.00004566674,0.0001468693,0.003567311,0.00005054336,0.0001916523,0.00001463774,0.0003092143,0.001037958,0.001004342,0.01973872,0.9737716],"study_design_scores_gemma":[0.0001239956,0.0001905227,0.001481819,0.001864638,0.0001905232,0.002722976,0.0000483243,0.0002204035,0.0008230246,0.001821505,0.9904881,0.00002423423],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001964027,0.9981288,0.0001871564,0.0004063157,0.0002211284,0.000003897362,0.00002098452,0.0000105798,0.0008246771],"genre_scores_gemma":[0.001215353,0.9969055,0.0002790703,0.0004855386,0.0002728148,0.000005848162,0.0000407791,0.00000181002,0.0007933017],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002533547,"threshold_uncertainty_score":0.008475602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00941036389523718,"score_gpt":0.2777189603102916,"score_spread":0.2683085964150544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}